

# Douglas L Mann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3600396/publications.pdf>

Version: 2024-02-01

376  
papers

38,276  
citations

3264

94  
h-index

3688

186  
g-index

390  
all docs

390  
docs citations

390  
times ranked

35348  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Seattle Heart Failure Model. <i>Circulation</i> , 2006, 113, 1424-1433.	1.6	1,744
2	Embryonic and Adult-Derived Resident Cardiac Macrophages Are Maintained through Distinct Mechanisms at Steady State and during Inflammation. <i>Immunity</i> , 2014, 40, 91-104.	6.6	1,120
3	Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). <i>Journal of the American College of Cardiology</i> , 1996, 27, 1201-1206.	1.2	1,098
4	Targeted Anticytokine Therapy in Patients With Chronic Heart Failure. <i>Circulation</i> , 2004, 109, 1594-1602.	1.6	1,062
5	Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1268.	3.8	976
6	Cytokines and Cytokine Receptors in Advanced Heart Failure. <i>Circulation</i> , 2001, 103, 2055-2059.	1.6	903
7	Inflammatory Mediators and the Failing Heart. <i>Circulation Research</i> , 2002, 91, 988-998.	2.0	886
8	Tumor Necrosis Factor- $\alpha$ and Tumor Necrosis Factor Receptors in the Failing Human Heart. <i>Circulation</i> , 1996, 93, 704-711.	1.6	833
9	Pathophysiologically Relevant Concentrations of Tumor Necrosis Factor- $\alpha$ Promote Progressive Left Ventricular Dysfunction and Remodeling in Rats. <i>Circulation</i> , 1998, 97, 1382-1391.	1.6	773
10	Mechanisms and Models in Heart Failure. <i>Circulation</i> , 2005, 111, 2837-2849.	1.6	740
11	Mechanisms and Models in Heart Failure. <i>Circulation</i> , 1999, 100, 999-1008.	1.6	706
12	Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16029-16034.	3.3	576
13	Innate Immunity and the Failing Heart. <i>Circulation Research</i> , 2015, 116, 1254-1268.	2.0	535
14	Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy. <i>Circulation</i> , 2001, 103, 2254-2259.	1.6	515
15	Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. <i>New England Journal of Medicine</i> , 2012, 366, 1859-1869.	13.9	511
16	TNF- $\alpha$ acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. <i>FASEB Journal</i> , 2005, 19, 362-370.	0.2	510
17	Role of innate and adaptive immune mechanisms in cardiac injury and repair. <i>Nature Reviews Immunology</i> , 2015, 15, 117-129.	10.6	479
18	Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 500.	3.8	457

#	ARTICLE	IF	CITATIONS
19	Desmin Mutation Responsible for Idiopathic Dilated Cardiomyopathy. <i>Circulation</i> , 1999, 100, 461-464.	1.6	420
20	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2533.	3.8	410
21	Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 5456-5461.	3.3	401
22	Basic mechanisms in heart failure: The cytokine hypothesis. <i>Journal of Cardiac Failure</i> , 1996, 2, 243-249.	0.7	392
23	Deep RNA Sequencing Reveals Dynamic Regulation of Myocardial Noncoding RNAs in Failing Human Heart and Remodeling With Mechanical Circulatory Support. <i>Circulation</i> , 2014, 129, 1009-1021.	1.6	391
24	Reappraising the role of inflammation in heart failure. <i>Nature Reviews Cardiology</i> , 2020, 17, 269-285.	6.1	389
25	Safety and Efficacy of a Soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in Patients With Advanced Heart Failure. <i>Circulation</i> , 1999, 99, 3224-3226.	1.6	367
26	Neurohormonal activation in heart failure with reduced ejection fraction. <i>Nature Reviews Cardiology</i> , 2017, 14, 30-38.	6.1	359
27	Results of Targeted Anti-Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure. <i>Circulation</i> , 2001, 103, 1044-1047.	1.6	358
28	Tissue Expression and Immunolocalization of Tumor Necrosis Factor- $\alpha$ in Postinfarction Dysfunctional Myocardium. <i>Circulation</i> , 1999, 99, 1492-1498.	1.6	353
29	Left Ventricular Remodeling in Transgenic Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor. <i>Circulation</i> , 2001, 104, 826-831.	1.6	353
30	Basic Mechanisms in Congestive Heart Failure. <i>Chest</i> , 1994, 105, 897-904.	0.4	350
31	Impact of Oxypurinol in Patients With Symptomatic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2301-2309.	1.2	350
32	A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 17378-17383.	3.3	321
33	The Emerging Role of Innate Immunity in the Heart and Vascular System. <i>Circulation Research</i> , 2011, 108, 1133-1145.	2.0	318
34	Sphingosine Mediates the Immediate Negative Inotropic Effects of Tumor Necrosis Factor- $\alpha$ in the Adult Mammalian Cardiac Myocyte. <i>Journal of Biological Chemistry</i> , 1997, 272, 4836-4842.	1.6	307
35	Tumor Necrosis Factor- $\alpha$ Provokes a Hypertrophic Growth Response in Adult Cardiac Myocytes. <i>Circulation</i> , 1997, 95, 1247-1252.	1.6	302
36	Expression and Functional Significance of Tumor Necrosis Factor Receptors in Human Myocardium. <i>Circulation</i> , 1995, 92, 1487-1493.	1.6	284

#	ARTICLE	IF	CITATIONS
37	Vagus Nerve Stimulation for the Treatment of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 149-158.	1.2	283
38	Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation. <i>Journal of Clinical Investigation</i> , 2019, 129, 2293-2304.	3.9	283
39	Infectious Complications in Patients With Left Ventricular Assist Device: Etiology and Outcomes in the Continuous-Flow Era. <i>Annals of Thoracic Surgery</i> , 2010, 90, 1270-1277.	0.7	265
40	Prediction of Mode of Death in Heart Failure. <i>Circulation</i> , 2007, 116, 392-398.	1.6	261
41	Stress-Activated Cytokines and The Heart: From Adaptation to Maladaptation. <i>Annual Review of Physiology</i> , 2003, 65, 81-101.	5.6	258
42	In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. <i>Lancet</i> , The, 2011, 378, 704-712.	6.3	257
43	The Emerging Role of MicroRNAs in Cardiac Remodeling and Heart Failure. <i>Circulation Research</i> , 2008, 103, 1072-1083.	2.0	247
44	Hemodynamic Regulation of Tumor Necrosis Factor- $\alpha$ Gene and Protein Expression in Adult Feline Myocardium. <i>Circulation Research</i> , 1997, 81, 187-195.	2.0	240
45	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. <i>Circulation</i> , 2015, 131, 1763-1771.	1.6	239
46	Myocardial Recovery and the Failing Heart. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2465-2472.	1.2	229
47	Cardiac-Specific Overexpression of Tumor Necrosis Factor- $\alpha$ Causes Oxidative Stress and Contractile Dysfunction in Mouse Diaphragm. <i>Circulation</i> , 2000, 102, 1690-1696.	1.6	223
48	Active Ghrelin Levels and Active to Total Ghrelin Ratio in Cancer-Induced Cachexia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2920-2926.	1.8	222
49	Distribution of lipids in 8,500 men with coronary artery disease. <i>American Journal of Cardiology</i> , 1995, 75, 1196-1201.	0.7	219
50	Mitral valve surgery in heart failure: Insights from the Acorn Clinical Trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 132, 568-577.e4.	0.4	219
51	TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. <i>Journal of Clinical Investigation</i> , 2007, 117, 2692-2701.	3.9	212
52	Efficacy and Safety of Spironolactone in Acute Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 950.	3.0	199
53	Circulating Interleukin-6 in Severe Heart Failure. <i>American Journal of Cardiology</i> , 1997, 79, 1128-1131.	0.7	195
54	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , 2019, 40, 2155-2163.	1.0	195

#	ARTICLE	IF	CITATIONS
55	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1764.	3.8	187
56	<i>Escherichia coli</i> LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 282, H2316-H2323.	1.5	174
57	Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF). <i>Journal of Cardiac Failure</i> , 2011, 17, 634-642.	0.7	171
58	Differential Expression of Heat Shock Proteins in Normal and Failing Human Hearts. <i>Journal of Molecular and Cellular Cardiology</i> , 1998, 30, 811-818.	0.9	170
59	Biomarkers of inflammation in heart failure. <i>Heart Failure Reviews</i> , 2010, 15, 331-341.	1.7	169
60	Heart Failure With Recovered Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 719-734.	1.2	160
61	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. <i>JACC: Heart Failure</i> , 2018, 6, 874-883.	1.9	159
62	Cardiovascular Phenotype in HFpEF Patients With or Without Diabetes. <i>Journal of the American College of Cardiology</i> , 2014, 64, 541-549.	1.2	157
63	Activation of Matrix Metalloproteinases in the Failing Human Heart. <i>Circulation</i> , 1998, 98, 1699-1702.	1.6	155
64	Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. <i>Cardiovascular Research</i> , 2002, 53, 822-830.	1.8	152
65	Experimental and Clinical Basis for the Use of Statins in Patients With Ischemic and Nonischemic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2008, 51, 415-426.	1.2	144
66	A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial). <i>European Heart Journal</i> , 2015, 36, 2297-2309.	1.0	137
67	Necrotic Myocardial Cells Release Damage-Associated Molecular Patterns That Provoke Fibroblast Activation In Vitro and Trigger Myocardial Inflammation and Fibrosis In Vivo. <i>Journal of the American Heart Association</i> , 2015, 4, e001993.	1.6	136
68	Tumor Necrosis Factor- $\alpha$ Confers Resistance to Hypoxic Injury in the Adult Mammalian Cardiac Myocyte. <i>Circulation</i> , 1998, 97, 1392-1400.	1.6	134
69	Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 292, H503-H509.	1.5	134
70	CD14-Deficient Mice Are Protected Against Lipopolysaccharide-Induced Cardiac Inflammation and Left Ventricular Dysfunction. <i>Circulation</i> , 2002, 106, 2608-2615.	1.6	131
71	Nuclear Factor- $\kappa$ B Protects the Adult Cardiac Myocyte Against Ischemia-Induced Apoptosis in a Murine Model of Acute Myocardial Infarction. <i>Circulation</i> , 2003, 108, 3075-3078.	1.6	131
72	Rationale and study design of the INcrease Of Vagal TonE in Heart Failure study: INOVATE-HF. <i>American Heart Journal</i> , 2012, 163, 954-962.e1.	1.2	130

#	ARTICLE	IF	CITATIONS
73	Comparable Performance of the Kansas City Cardiomyopathy Questionnaire in Patients With Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2013, 6, 1139-1146.	1.6	130
74	Angiotensin Receptorâ€“Nepriylsin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021, 385, 1845-1855.	13.9	130
75	Clinical Evaluation of the CorCap Cardiac Support Device in Patients With Dilated Cardiomyopathy. <i>Annals of Thoracic Surgery</i> , 2007, 84, 1226-1235.	0.7	128
76	Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. <i>Journal of the American College of Cardiology</i> , 1999, 33, 1935-1942.	1.2	126
77	Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 819-824.	0.3	125
78	Role of MicroRNAs in Cardiac Remodeling and Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 171-182.	1.3	123
79	Angiotensin II Induces Tumor Necrosis Factor Biosynthesis in the Adult Mammalian Heart Through a Protein Kinase Câ€“Dependent Pathway. <i>Circulation</i> , 2002, 105, 2198-2205.	1.6	121
80	Oneâ€“year followâ€“up results from AUGMENTâ€“CHF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 314-325.	2.9	118
81	Extracellular matrix remodeling following myocardial injury. <i>Annals of Medicine</i> , 2003, 35, 316-326.	1.5	117
82	Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H461-H468.	1.5	115
83	Load-Dependent and -Independent Regulation of Proinflammatory Cytokine and Cytokine Receptor Gene Expression in the Adult Mammalian Heart. <i>Circulation</i> , 2002, 105, 2192-2197.	1.6	114
84	Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 287, H1303-H1311.	1.5	113
85	THE ROLE OF CYTOKINES IN THE FAILING HUMAN HEART. <i>Cardiology Clinics</i> , 1998, 16, 645-656.	0.9	109
86	Hemodynamic Effects of Tezosentan, an Intravenous Dual Endothelin Receptor Antagonist, in Patients With Class III to IV Congestive Heart Failure. <i>Circulation</i> , 2001, 103, 973-980.	1.6	108
87	Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a midâ€“range ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1597-1605.	2.9	108
88	Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 292, H1561-H1567.	1.5	106
89	Sustained Benefits of the CorCap Cardiac Support Device on Left Ventricular Remodeling: Three Year Follow-up Results From the Acorn Clinical Trial. <i>Annals of Thoracic Surgery</i> , 2007, 84, 1236-1242.	0.7	105
90	Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. <i>Journal of the American College of Cardiology</i> , 2000, 36, 208-212.	1.2	98

#	ARTICLE	IF	CITATIONS
91	Diabetic Cardiomyopathy. <i>Heart Failure Clinics</i> , 2012, 8, 619-631.	1.0	98
92	Effects of Tumor Necrosis Factor Gene Polymorphisms on Patients With Congestive Heart Failure. <i>Circulation</i> , 1998, 97, 2499-2501.	1.6	97
93	Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. <i>Journal of Cardiac Failure</i> , 2002, 8, 390-398.	0.7	97
94	Adaptive and Maladaptive Effects of SMAD3 Signaling in the Adult Heart After Hemodynamic Pressure Overloading. <i>Circulation: Heart Failure</i> , 2009, 2, 633-642.	1.6	97
95	Inflammatory Mediators and the Failing Heart: A Translational Approach. <i>Current Molecular Medicine</i> , 2003, 3, 161-182.	0.6	96
96	Tumor necrosis factor- $\alpha$ confers cardioprotection through ectopic expression of keratins K8 and K18. <i>Nature Medicine</i> , 2015, 21, 1076-1084.	15.2	93
97	Targeted Anticytokine Therapy and the Failing Heart. <i>American Journal of Cardiology</i> , 2005, 95, 9-16.	0.7	91
98	Cardiorenal Rescue Study in Acute Decompensated Heart Failure: Rationale and Design of CARRESS-HF, for the Heart Failure Clinical Research Network. <i>Journal of Cardiac Failure</i> , 2012, 18, 176-182.	0.7	91
99	Cyclooxygenase-2 Inhibitor Treatment Improves Left Ventricular Function and Mortality in a Murine Model of Doxorubicin-Induced Heart Failure. <i>Circulation</i> , 2004, 109, 1428-1433.	1.6	90
100	Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 129-136.	1.9	90
101	Stress activated cytokines and the heart. <i>Cytokine and Growth Factor Reviews</i> , 1996, 7, 341-354.	3.2	89
102	Hypogonadism in male patients with cancer. <i>Cancer</i> , 2006, 106, 2583-2591.	2.0	88
103	Differential Regulation of Mitogen-Activated Protein Kinases in the Failing Human Heart in Response to Mechanical Unloading. <i>Circulation</i> , 2001, 104, 2273-2276.	1.6	87
104	Mitral valve repair in heart failure: Five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, 569-574.e1.	0.4	87
105	NHLBI's Program for VAD Therapy for Moderately Advanced Heart Failure: The REVIVE-IT Pilot Trial. <i>Journal of Cardiac Failure</i> , 2010, 16, 855-858.	0.7	86
106	Cellular remodeling in heart failure disrupts KATP channel-dependent stress tolerance. <i>EMBO Journal</i> , 2003, 22, 1732-1742.	3.5	85
107	Beneficial effects of the CorCap cardiac support device: Five-year results from the Acorn Trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 1036-1042.	0.4	85
108	Role of inflammatory cells in fibroblast activation. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 93, 143-148.	0.9	85

#	ARTICLE	IF	CITATIONS
109	Transforming growth factor- $\beta$ 2 receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. <i>Basic Research in Cardiology</i> , 2008, 103, 60-68.	2.5	84
110	Review of Side-Effect Profile of Combination Ezetimibe and Statin Therapy in Randomized Clinical Trials. <i>American Journal of Cardiology</i> , 2008, 101, 1606-1613.	0.7	81
111	Comparison of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction Among Those With Versus Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2010, 105, 373-377.	0.7	81
112	Intra-Aortic Balloon Counterpulsation in Patients With Chronic Heart Failure and Cardiogenic Shock: Clinical Response and Predictors of Stabilization. <i>Journal of Cardiac Failure</i> , 2015, 21, 868-876.	0.7	81
113	Circulating Levels of Tumor Necrosis Factor Correlate With Indexes of Depressed Heart Rate Variability. <i>Chest</i> , 2003, 123, 716-724.	0.4	80
114	Nitric Oxide Provokes Tumor Necrosis Factor- $\alpha$ Expression in Adult Feline Myocardium Through a cGMP-Dependent Pathway. <i>Circulation</i> , 2000, 102, 1302-1307.	1.6	79
115	Extracellular Matrix Turnover and Inflammatory Markers Independently Predict Functional Status and Outcome in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, 467-474.	0.7	79
116	The Development of Myocardial Fibrosis in Transgenic Mice With Targeted Overexpression of Tumor Necrosis Factor Requires Mast Cell-Fibroblast Interactions. <i>Circulation</i> , 2011, 124, 2106-2116.	1.6	79
117	An overview of tumor necrosis factor $\alpha$ and the failing human heart. <i>Current Opinion in Cardiology</i> , 1999, 14, 206.	0.8	77
118	Widespread Down-Regulation of Cardiac Mitochondrial and Sarcomeric Genes in Patients With Sepsis*. <i>Critical Care Medicine</i> , 2017, 45, 407-414.	0.4	76
119	Myocardial Proinflammatory Cytokine Expression and Left Ventricular Remodeling in Patients With Chronic Mitral Regurgitation. <i>Circulation</i> , 2003, 107, 831-837.	1.6	75
120	Activation and Functional Significance of the Renin-Angiotensin System in Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor. <i>Circulation</i> , 2003, 108, 598-604.	1.6	73
121	Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. <i>Cardiovascular Research</i> , 2004, 63, 433-442.	1.8	71
122	Proapoptotic Effects of Caspase-1/Interleukin-Converting Enzyme Dominate in Myocardial Ischemia. <i>Circulation Research</i> , 2005, 96, 1103-1109.	2.0	71
123	Recent insights into the role of tumor necrosis factor in the failing heart. , 2001, 6, 71-80.		70
124	Increased Myocardial Gene Expression of Tumor Necrosis Factor- $\alpha$ and Nitric Oxide Synthase-2. <i>Circulation</i> , 2002, 105, 1537-1540.	1.6	68
125	Targeted Overexpression of Noncleavable and Secreted Forms of Tumor Necrosis Factor Provokes Disparate Cardiac Phenotypes. <i>Circulation</i> , 2004, 109, 262-268.	1.6	68
126	Epidemiology and Natural History of Recovery of Left Ventricular Function in Recent Onset Dilated Cardiomyopathies. <i>Current Heart Failure Reports</i> , 2013, 10, 321-330.	1.3	68



#	ARTICLE	IF	CITATIONS
127	Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1199-1209.	1.4	68
128	The NHLBI REVIVE-IT study: Understanding its discontinuation in the context of current left ventricular assist device therapy. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1277-1283.	0.3	67
129	Effects of Phosphodiesterase Type 5 Inhibition on Systemic and Pulmonary Hemodynamics and Ventricular Function in Patients With Severe Symptomatic Aortic Stenosis. <i>Circulation</i> , 2012, 125, 2353-2362.	1.6	66
130	Positioning of Inflammatory Biomarkers in the Heart Failure Landscape. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 485-492.	1.1	66
131	Abnormal Global Longitudinal Strain Predicts Future Deterioration of Left Ventricular Function in Heart Failure Patients With a Recovered Left Ventricular Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	65
132	Imaging Systemic Inflammatory Networks in Ischemic Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1583-1591.	1.2	64
133	Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury. <i>JCI Insight</i> , 2018, 3, .	2.3	63
134	Desmin mediates TNF- $\alpha$ -induced aggregate formation and intercalated disk reorganization in heart failure. <i>Journal of Cell Biology</i> , 2008, 181, 761-775.	2.3	62
135	SR compartment calcium and cell apoptosis in SERCA overexpression. <i>Cell Calcium</i> , 1999, 26, 25-36.	1.1	61
136	Proteomic Signatures of Heart Failure Relation to Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1982-1994.	1.2	61
137	Cytokines as Emerging Targets in the Treatment of Heart Failure. <i>Trends in Cardiovascular Medicine</i> , 2000, 10, 216-223.	2.3	60
138	The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. <i>Journal of the American College of Cardiology</i> , 2000, 36, 523-528.	1.2	60
139	New Therapeutics for Chronic Heart Failure. <i>Annual Review of Medicine</i> , 2002, 53, 59-74.	5.0	60
140	MicroRNAs and the Failing Heart. <i>New England Journal of Medicine</i> , 2007, 356, 2644-2645.	13.9	60
141	Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 294, H1490-H1496.	1.5	60
142	The feasibility and safety of Algisyl-LVR $\beta$ as a method of left ventricular augmentation in patients with dilated cardiomyopathy: Initial first in man clinical results. <i>International Journal of Cardiology</i> , 2015, 199, 18-24.	0.8	60
143	Brief murine myocardial I/R induces chemokines in a TNF- $\alpha$ -independent manner: role of oxygen radicals. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 281, H2549-H2558.	1.5	59
144	Cross-sectional echocardiographic assessment of regional left ventricular performance and myocardial perfusion. <i>Progress in Cardiovascular Diseases</i> , 1986, 29, 1-52.	1.6	58

#	ARTICLE	IF	CITATIONS
145	Targeted Overexpression of Transmembrane Tumor Necrosis Factor Provokes a Concentric Cardiac Hypertrophic Phenotype. <i>Circulation</i> , 2003, 108, 1002-1008.	1.6	58
146	The Cytoprotective Effects of Tumor Necrosis Factor Are Conveyed Through Tumor Necrosis Factor Receptor-associated Factor 2 in the Heart. <i>Circulation: Heart Failure</i> , 2010, 3, 157-164.	1.6	58
147	The Adverse Impact of Diabetes Mellitus on Left Ventricular Remodeling and Function in Patients With Severe Aortic Stenosis. <i>Circulation: Heart Failure</i> , 2011, 4, 286-292.	1.6	58
148	Speckle Strain Echocardiography Predicts Outcome in Patients with Heart Failure with both Depressed and Preserved Left Ventricular Ejection Fraction. <i>Echocardiography</i> , 2015, 32, 71-78.	0.3	58
149	Left Ventricular Assist Devices and the Failing Heart. <i>Circulation</i> , 1998, 98, 2367-2369.	1.6	57
150	Myocardial B cells are a subset of circulating lymphocytes with delayed transit through the heart. <i>JCI Insight</i> , 2020, 5, .	2.3	57
151	Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, 185-192.	0.7	55
152	Autonomic Modulation for the Management of Patients with Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 619-628.	1.6	54
153	Tumor necrosis factor- $\beta$ and the failing human heart-TNF $\beta$ and heart failure. <i>Clinical Cardiology</i> , 1995, 18, IV20-IV27.	0.7	53
154	Cytokines in Heart Failure: Pathogenetic Mechanisms and Potential Treatment. <i>Proceedings of the Association of American Physicians</i> , 1999, 111, 423-428.	2.1	53
155	Improving Outcomes in Heart Failure. <i>Circulation</i> , 2002, 105, 2810-2812.	1.6	53
156	Effects of changes in left ventricular contractility on indexes of contractility in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H2504-H2510.	1.5	53
157	Structural and Functional Phenotyping of the Failing Heart. <i>JACC: Heart Failure</i> , 2017, 5, 772-781.	1.9	53
158	Functional Significance of Hemodynamic Overload-induced Expression of Leukemia-Inhibitory Factor in the Adult Mammalian Heart. <i>Circulation</i> , 2001, 103, 1296-1302.	1.6	52
159	Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1509-1516.	1.9	51
160	Oxidative Stress Promotes Ligand-independent and Enhanced Ligand-dependent Tumor Necrosis Factor Receptor Signaling. <i>Journal of Biological Chemistry</i> , 2008, 283, 23419-23428.	1.6	50
161	Tumor Necrosis Factor Receptor-associated Factor 2 Mediates Mitochondrial Autophagy. <i>Circulation: Heart Failure</i> , 2015, 8, 175-187.	1.6	49
162	Duality of innate stress responses in cardiac injury, repair, and remodeling. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 37, 801-811.	0.9	48

#	ARTICLE	IF	CITATIONS
163	Tumor necrosis factor-induced signal transduction and left ventricular remodeling. <i>Journal of Cardiac Failure</i> , 2002, 8, S379-S386.	0.7	46
164	Angiotensin-Receptor Blockade in Acute Myocardial Infarction – A Matter of Dose. <i>New England Journal of Medicine</i> , 2003, 349, 1963-1965.	13.9	46
165	Basic mechanisms of left ventricular remodeling: the contribution of wall stress. <i>Journal of Cardiac Failure</i> , 2004, 10, S202-S206.	0.7	46
166	Neuromodulation of the Failing Heart. <i>JACC Basic To Translational Science</i> , 2016, 1, 95-106.	1.9	46
167	Role of the Innate Immune System in Acute Viral Myocarditis. <i>Basic Research in Cardiology</i> , 2009, 104, 228-237.	2.5	45
168	Cardiac remodelling and myocardial recovery: lost in translation?. <i>European Journal of Heart Failure</i> , 2010, 12, 789-796.	2.9	45
169	Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure. <i>Stroke</i> , 2016, 47, 2031-2037.	1.0	44
170	Impact of Preeclampsia on Clinical and Functional Outcomes in Women With Peripartum Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	44
171	Innate immunity in the adult mammalian heart: for whom the cell tolls. <i>Transactions of the American Clinical and Climatological Association</i> , 2010, 121, 34-50; discussion 50-1.	0.9	44
172	Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure. <i>Circulation</i> , 2020, 141, 1463-1476.	1.6	42
173	Tumor Necrosis Factor and Viral Myocarditis: The Fine Line Between Innate and Inappropriate Immune Responses in the Heart. <i>Circulation</i> , 2001, 103, 626-629.	1.6	41
174	Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. <i>ESC Heart Failure</i> , 2020, 7, 76-84.	1.4	41
175	Effects of age on ventricular performance during graded supine exercise. <i>American Heart Journal</i> , 1986, 111, 108-115.	1.2	40
176	Apoptosis and the heart: a decade of progress. <i>Journal of Molecular and Cellular Cardiology</i> , 2005, 38, 1-2.	0.9	40
177	Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 298, H1079-H1087.	1.5	40
178	The Role of Innate Immune Responses in the Heart in Health and Disease. <i>Trends in Cardiovascular Medicine</i> , 2004, 14, 1-7.	2.3	39
179	Soluble Tumor Necrosis Factor Receptors and Heart Failure Risk in Older Adults. <i>Circulation: Heart Failure</i> , 2014, 7, 5-11.	1.6	39
180	Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 789-799.	1.9	39

#	ARTICLE	IF	CITATIONS
181	Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2013, 6, 988-997.	1.6	38
182	Therapeutic targeting of innate immunity in the failing heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 51, 594-599.	0.9	37
183	Load-Dependent Changes in Left Ventricular Structure and Function in a Pathophysiologically Relevant Murine Model of Reversible Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e004351.	1.6	37
184	Cardiac Disease in Cancer Patients: An Overview. <i>Progress in Cardiovascular Diseases</i> , 2010, 53, 80-87.	1.6	36
185	Use of Biomarkers in the Management of Heart Failure. <i>Circulation</i> , 2003, 107, 1231-1233.	1.6	35
186	Inhibition of PPAR- $\alpha$ activity in mice with cardiac-restricted expression of tumor necrosis factor: potential role of TGF- $\beta$ 2/Smad3. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 292, H1443-H1451.	1.5	35
187	Heart Failure Diagnosis, Readmission, and Mortality Prediction Using Machine Learning and Artificial Intelligence Models. <i>Current Epidemiology Reports</i> , 2020, 7, 212-219.	1.1	35
188	Comparison of outcomes of white versus black patients hospitalized with heart failure and preserved ejection fraction**The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.. <i>American Journal of Cardiology</i> , 2004, 94, 1003-1007.	0.7	34
189	Left Ventricular Size and Shape: Determinants of Mechanical Signal Transduction Pathways. <i>Heart Failure Reviews</i> , 2005, 10, 95-100.	1.7	34
190	Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. <i>Journal of Psychosomatic Research</i> , 2011, 71, 13-17.	1.2	34
191	Functional significance of the discordance between transcriptional profile and left ventricular structure/function during reverse remodeling. <i>JCI Insight</i> , 2016, 1, e86038.	2.3	33
192	Targeted cancer therapeutics: the heartbreak of success. <i>Nature Medicine</i> , 2006, 12, 881-882.	15.2	32
193	The Emerging Role of B Lymphocytes in Cardiovascular Disease. <i>Annual Review of Immunology</i> , 2020, 38, 99-121.	9.5	32
194	Inflammatory mediators in heart failure: homogeneity through heterogeneity. <i>Lancet, The</i> , 1999, 353, 1812-1813.	6.3	31
195	New Predictive Models of Heart Failure Mortality Using Time-Series Measurements and Ensemble Models. <i>Circulation: Heart Failure</i> , 2011, 4, 456-462.	1.6	31
196	Prevalence of lactic acidemia in patients with advanced heart failure and depressed cardiac output. <i>European Journal of Heart Failure</i> , 2017, 19, 1027-1033.	2.9	31
197	Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. <i>Journal of Cardiac Failure</i> , 2002, 8, 306-314.	0.7	30
198	Dysferlin Mediates the Cytoprotective Effects of TRAF2 Following Myocardial Ischemia Reperfusion Injury. <i>Journal of the American Heart Association</i> , 2014, 3, e000662.	1.6	30

#	ARTICLE	IF	CITATIONS
199	Left ventricular assist device-induced reverse remodeling: it's not just about myocardial recovery. Expert Review of Medical Devices, 2017, 14, 15-26.	1.4	30
200	Hepcidin in anemia of chronic heart failure. American Journal of Hematology, 2011, 86, 107-109.	2.0	29
201	Tumor Necrosis Factor Receptor-Associated Factor 2 Signaling Provokes Adverse Cardiac Remodeling in the Adult Mammalian Heart. Circulation: Heart Failure, 2013, 6, 535-543.	1.6	29
202	Prognostic Significance of Biomarkers in Predicting Outcome in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. Circulation: Heart Failure, 2013, 6, 461-472.	1.6	28
203	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation, 2022, 145, 87-89.	1.6	28
204	Tumor Necrosis Factor- $\beta$ Is Persistently Expressed in Cardiac Allografts in the Absence of Histological or Clinical Evidence of Rejection. Transplantation Proceedings, 1998, 30, 875-877.	0.3	27
205	Functional significance of inflammatory mediators in a murine model of resuscitated hemorrhagic shock. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H1272-H1277.	1.5	27
206	Normalization of cardiac structure and function after regression of cardiac hypertrophy. American Heart Journal, 1994, 128, 333-343.	1.2	26
207	Failure of benefit and early hazard of bucindolol for Class IV heart failure. Journal of Cardiac Failure, 2003, 9, 266-277.	0.7	26
208	Advanced Heart Failure and Transplant Cardiology: A Subspecialty Is Born. Journal of the American College of Cardiology, 2009, 53, 834-836.	1.2	26
209	Clinical applications of miRNAs in cardiac remodeling and heart failure. Personalized Medicine, 2010, 7, 531-548.	0.8	26
210	The Heartmate Risk Score Predicts Morbidity and Mortality in Unselected Left Ventricular Assist Device Recipients and Risk Stratifies INTERMACS Class 1 Patients. JACC: Heart Failure, 2015, 3, 283-290.	1.9	26
211	Cognitive Decline Over Time in Patients With Systolic Heart Failure. JACC: Heart Failure, 2019, 7, 1042-1053.	1.9	26
212	Predictive Value of Cardiopulmonary Exercise Testing Parameters in Ambulatory Advanced Heart Failure. JACC: Heart Failure, 2021, 9, 226-236.	1.9	26
213	Heart Failure Guidelines, Performance Measures, and the Practice of Medicine. Journal of the American College of Cardiology, 2010, 56, 2077-2080.	1.2	25
214	Communication in the Heart: the Role of the Innate Immune System in Coordinating Cellular Responses to Ischemic Injury. Journal of Cardiovascular Translational Research, 2012, 5, 827-836.	1.1	25
215	<sup>2</sup>CHA<sub>2</sub>DS<sub>2</sub>-VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. European Journal of Heart Failure, 2016, 18, 1261-1266.	2.9	25
216	Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment. ESC Heart Failure, 2018, 5, 800-808.	1.4	25

#	ARTICLE	IF	CITATIONS
217	New Insights into Mechanisms of Action of Carvedilol Treatment in Chronic Heart Failure Patientsâ€”A Matter of Time for Contractility. <i>Journal of Cardiac Failure</i> , 2012, 18, 183-193.	0.7	24
218	Is Myocardial Recovery Possible and How Do You Measure It?. <i>Current Cardiology Reports</i> , 2012, 14, 293-298.	1.3	24
219	Serum Biomarkers in Severe Refractory Cardiogenic Shock. <i>JACC: Heart Failure</i> , 2013, 1, 200-206.	1.9	24
220	Recurrent Stroke in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. <i>Cerebrovascular Diseases</i> , 2014, 38, 176-181.	0.8	24
221	Mechanisms and Models in Heart Failure. <i>Circulation Research</i> , 2021, 128, 1435-1450.	2.0	24
222	Repetitive Myocardial Ischemia Promotes Coronary Growth in the Adult Mammalian Heart. <i>Journal of the American Heart Association</i> , 2013, 2, e000343.	1.6	23
223	Angiotensin II as an inflammatory mediator: evolving concepts in the role of the renin angiotensin system in the failing heart. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 7-9.	1.3	22
224	Effect of the Soluble TNFâ€”Antagonist Etanercept on Tumor Necrosis Factor Bioactivity and Stability. <i>Clinical and Translational Science</i> , 2008, 1, 142-145.	1.5	22
225	Circulating p53-Responsive MicroRNAs as Predictive Biomarkers in Heart Failure After Acute Myocardial Infarction. <i>Circulation Research</i> , 2013, 113, 242-244.	2.0	22
226	Recent Insights into the Role of Tumor Necrosis Factor in the Failing Heart. <i>Developments in Cardiovascular Medicine</i> , 2001, , 3-12.	0.1	22
227	Single- versus dual-chamber sensor-driven pacing: Comparison of cardiac outputs. <i>American Heart Journal</i> , 1991, 122, 728-732.	1.2	21
228	Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2013, 6, 862-868.	1.6	21
229	Quality of Anticoagulation Control in Preventing Adverse Events in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2015, 8, 504-509.	1.6	21
230	The HeartMate Risk Score Identifies Patients With Similar Mortality Risk Across All INTERMACS Profiles in a Large Multicenter Analysis. <i>JACC: Heart Failure</i> , 2016, 4, 950-958.	1.9	21
231	Plasma concentrations of tumor necrosis factor- in cats with congestive heart failure. <i>American Journal of Veterinary Research</i> , 2002, 63, 640-642.	0.3	20
232	Pathophysiology of Heart Failure. , 2012, , 487-504.		20
233	Digoxin treatment in heart failure â€” Unveiling risk by cluster analysis of DIG data. <i>International Journal of Cardiology</i> , 2011, 150, 264-269.	0.8	19
234	Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure â€” A Pilot Study. <i>Journal of Obesity &amp; Weight Loss Therapy</i> , 2012, 02, 1-8.	0.1	19

#	ARTICLE	IF	CITATIONS
235	Cardiac Risk Markers and Response to Depression Treatment in Patients With Coronary Heart Disease. <i>Psychosomatic Medicine</i> , 2016, 78, 49-59.	1.3	19
236	Diagnosis and management of adult hereditary cardio-neuromuscular disorders: A model for the multidisciplinary care of complex genetic disorders. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 51-58.	2.3	19
237	Immunomodulatory role of nonneuronal cholinergic signaling in myocardial injury. <i>JCI Insight</i> , 2019, 4, .	2.3	19
238	The fractional shortening-velocity ratio: Validation of a new echocardiographic doppler method for identifying patients with significant aortic stenosis. <i>Journal of the American College of Cardiology</i> , 1990, 15, 1578-1584.	1.2	18
239	Contemporary Medical Options for Treating Patients With Heart Failure. <i>Circulation</i> , 2002, 105, 2244-2246.	1.6	18
240	Advanced Heart Failure and Transplant Cardiology: A Subspecialty is Born. <i>Journal of Cardiac Failure</i> , 2009, 15, 98-100.	0.7	18
241	Are Synthetic Data Derivatives the Future of Translational Medicine?. <i>JACC Basic To Translational Science</i> , 2018, 3, 716-718.	1.9	18
242	TNF receptor-activated factor 2 mediates cardiac protection through noncanonical NF- $\kappa$ B signaling. <i>JCI Insight</i> , 2018, 3, .	2.3	18
243	Effects of Vesnarinone on Peripheral Circulating Levels of Cytokines and Cytokine Receptors in Patients With Heart Failure. <i>Chest</i> , 2001, 120, 453-459.	0.4	17
244	Mitochondrial tolerance to stress impaired in failing heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2003, 35, 1161-1166.	0.9	17
245	The pharmacokinetics of etanercept in patients with heart failure. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 191-192.	1.1	16
246	Spectrum of Pleiotropic Effects of Statins in Heart Failure. <i>Heart Failure Clinics</i> , 2008, 4, 153-161.	1.0	16
247	COVID-19 Clinical Trials. <i>JACC Basic To Translational Science</i> , 2020, 5, 501-517.	1.9	16
248	Developmental changes in myocardial B cells mirror changes in B cells associated with different organs. <i>JCI Insight</i> , 2020, 5, .	2.3	16
249	Relationship of functional recovery to scar contraction after myocardial infarction in the canine left ventricle. <i>American Heart Journal</i> , 1989, 117, 819-829.	1.2	15
250	Coronary Collaterals Predict Improved Survival and Allograft Function in Patients With Coronary Allograft Vasculopathy. <i>Circulation: Heart Failure</i> , 2013, 6, 773-784.	1.6	15
251	Cognitive Function in Ambulatory Patients with Systolic Heart Failure: Insights from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. <i>PLoS ONE</i> , 2014, 9, e113447.	1.1	15
252	Quality of life and treatment preference for ventricular assist device therapy in ambulatory advanced heart failure: A report from the REVIVAL study. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 27-36.	0.3	15

#	ARTICLE	IF	CITATIONS
253	Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 692990.	1.1	15
254	Interleukin-6 and Viral Myocarditis: The Yin-Yang of Cardiac Innate Immune Responses. <i>Journal of Molecular and Cellular Cardiology</i> , 2001, 33, 1551-1553.	0.9	14
255	The Emerging Role of Small Non-coding RNAs in the Failing Heart: Big Hopes for Small Molecules. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 149-149.	1.3	14
256	Impaired Protein Quality Control During Left Ventricular Remodeling in Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	14
257	Ambulatory Advanced Heart Failure in Women. <i>JACC: Heart Failure</i> , 2019, 7, 602-611.	1.9	14
258	Relation of tissue Doppler-derived myocardial velocities to serum levels and myocardial gene expression of tumor necrosis factor-alpha and inducible nitric oxide synthase in patients with ischemic cardiomyopathy having coronary artery bypass grafting. <i>American Journal of Cardiology</i> , 2002, 90, 708-712.	0.7	13
259	Designs for Mechanical Circulatory Support Device Studies. <i>Journal of Cardiac Failure</i> , 2007, 13, 63-74.	0.7	13
260	Myocardial Expression Levels of Micro-Ribonucleic Acids in Patients With Left Ventricular Assist Devices. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2279-2281.	1.2	13
261	The first prognostic model for stroke and death in patients with systolic heart failure. <i>Journal of Cardiology</i> , 2016, 68, 100-103.	0.8	13
262	Registry Evaluation of Vital Information for VADs in Ambulatory Life (REVIVAL): Rationale, design, baseline characteristics, and inclusion criteria performance. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 7-15.	0.3	13
263	Tumor necrosis factor- $\alpha$ and tumor necrosis factor receptors in human heart failure. <i>Heart Failure Reviews</i> , 1996, 1, 211-219.	1.7	12
264	The Metabolic Syndrome and Mortality in an Ethnically Diverse Heart Failure Population. <i>Journal of Cardiac Failure</i> , 2008, 14, 590-595.	0.7	12
265	National Institutes of Health Career Development Awards for Cardiovascular Physician-Scientists. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1816-1827.	1.2	12
266	Targeting Myocardial Energetics in the Failing Heart. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	12
267	COVID-19 Clinical Trials. <i>JACC: CardioOncology</i> , 2020, 2, 254-269.	1.7	12
268	Management of Heart Failure Patients with Reduced Ejection Fraction. , 2012, , 543-577.		12
269	TNF $\alpha$ decreases $\beta$ -MHC expression by a NO mediated pathway: role of E-box transcription factors for cardiomyocyte specific gene regulation. <i>Cardiovascular Research</i> , 2002, 53, 460-469.	1.8	11
270	Antiinflammatory therapy in myocarditis. <i>Current Opinion in Cardiology</i> , 2003, 18, 189-193.	0.8	11



#	ARTICLE	IF	CITATIONS
271	Anti-angiotensin Therapy: New Perspectives. <i>Cardiology Clinics</i> , 2007, 25, 573-580.	0.9	11
272	The vagus nerve and autonomic imbalance in heart failure: past, present, and future. <i>Heart Failure Reviews</i> , 2011, 16, 97-99.	1.7	11
273	Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure—Subanalysis of the WARCEF Trial. <i>Circulation Journal</i> , 2016, 80, 619-626.	0.7	11
274	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021, 8, 5531-5541.	1.4	11
275	Rethinking Phase II clinical trial design in heart failure. <i>Clinical Investigation</i> , 2013, 3, 57-68.	0.0	11
276	TRAF2, an Innate Immune Sensor, Reciprocally Regulates Mitophagy and Inflammation to Maintain Cardiac Myocyte Homeostasis. <i>JACC Basic To Translational Science</i> , 2022, 7, 223-243.	1.9	11
277	Functional relation between infarct thickness and regional systolic function in the acutely and subacutely infarcted canine left ventricle. <i>Journal of the American College of Cardiology</i> , 1989, 14, 481-488.	1.2	10
278	Treatment of Heart Failure Beyond Practice Guidelines Role of Cardiac Remodeling. <i>Circulation Journal</i> , 2008, 72, A1-A7.	0.7	10
279	Sphingosine 1-Phosphate as a Therapeutic Target in Heart Failure. <i>Circulation</i> , 2012, 125, 2692-2694.	1.6	10
280	Stroke in Heart Failure in Sinus Rhythm: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction Trial. <i>Cerebrovascular Diseases</i> , 2013, 36, 74-78.	0.8	9
281	Vagal nerve stimulation for heart failure: new pieces to the puzzle?. <i>European Journal of Heart Failure</i> , 2015, 17, 125-127.	2.9	9
282	Impact of Socioeconomic Factors on Patient Desire for Early LVAD Therapy Prior to Inotrope Dependence. <i>Journal of Cardiac Failure</i> , 2020, 26, 316-323.	0.7	9
283	Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure. <i>Frontiers in Physiology</i> , 2022, 13, 857538.	1.3	9
284	Introducing JACC: Basic to Translational Science. <i>JACC Basic To Translational Science</i> , 2016, 1, 1-2.	1.9	8
285	Cardiac Sympathetic-Parasympathetic Interaction. <i>JACC Basic To Translational Science</i> , 2020, 5, 811-814.	1.9	8
286	Unsupervised cluster analysis of patients with recovered left ventricular ejection fraction identifies unique clinical phenotypes. <i>PLoS ONE</i> , 2021, 16, e0248317.	1.1	8
287	Signaling pathways involved in left ventricular remodeling: Summation. <i>Journal of Cardiac Failure</i> , 2002, 8, S387-S388.	0.7	7
288	Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 1241-1252.	0.3	7

#	ARTICLE	IF	CITATIONS
289	Statement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States. <i>Circulation: Heart Failure</i> , 2013, 6, e1-e11.	1.6	7
290	The evolution of modern theory and therapy for heart failure. <i>Progress in Pediatric Cardiology</i> , 2014, 37, 9-12.	0.2	7
291	Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. <i>American Journal of Cardiology</i> , 2015, 116, 904-912.	0.7	7
292	Is It Time for a New Taxonomy for Heart Failure?. <i>Journal of Cardiac Failure</i> , 2016, 22, 710-712.	0.7	7
293	Beta-blockers for the treatment of heart failure with a mid-range ejection fraction: deja-vu all over again?. <i>European Heart Journal</i> , 2018, 39, 36-38.	1.0	7
294	Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial. <i>ESC Heart Failure</i> , 2019, 6, 297-307.	1.4	7
295	RNA Vaccines for COVID-19. <i>JACC Basic To Translational Science</i> , 2020, 5, 1240-1243.	1.9	7
296	Comorbid Conditions and Health-Related Quality of Life in Ambulatory Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2020, 13, e006858.	1.6	7
297	Caregiver Health-Related Quality of Life, Burden, and Patient Outcomes in Ambulatory Advanced Heart Failure: A Report From REVIVAL. <i>Journal of the American Heart Association</i> , 2021, 10, e019901.	1.6	6
298	Early natural history of regional left ventricular dysfunction after experimental myocardial infarction. <i>American Heart Journal</i> , 1988, 115, 538-546.	1.2	5
299	Heart Failure Guidelines, Performance Measures, and the Practice of Medicine. <i>Journal of Cardiac Failure</i> , 2010, 16, 915-918.	0.7	5
300	Translational medicine: mitigating risks for investigators. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 327-328.	21.5	5
301	How to Build an Integrated Biobank: The Washington University Translational Cardiovascular Biobank & Repository Experience. <i>Clinical and Translational Science</i> , 2013, 6, 226-231.	1.5	5
302	Getting Pumped about Heart Failure. <i>Cell Metabolism</i> , 2014, 19, 896-897.	7.2	5
303	Resting Heart Rate and Ischemic Stroke in Patients with Heart Failure. <i>Cerebrovascular Diseases</i> , 2017, 44, 43-50.	0.8	5
304	The Tafamidis Drug Development Program. <i>JACC Basic To Translational Science</i> , 2018, 3, 871-873.	1.9	5
305	Ischemia reperfusion injury provokes adverse left ventricular remodeling in dysferlin-deficient hearts through a pathway that involves TIRAP dependent signaling. <i>Scientific Reports</i> , 2020, 10, 14129.	1.6	5
306	Frailty Measures of Patient-reported Activity and Fatigue May Predict 1-year Outcomes in Ambulatory Advanced Heart Failure: A Report From the REVIVAL Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 765-774.	0.7	5

#	ARTICLE	IF	CITATIONS
307	Modulation of left ventricular dilation remodeling with epicardial restraint devices in postmyocardial infarction heart failure. <i>Current Heart Failure Reports</i> , 2009, 6, 229-235.	1.3	4
308	Statement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States. <i>Annals of Thoracic Surgery</i> , 2012, 94, 2147-2158.	0.7	4
309	Statement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States: Executive Summary. <i>Annals of Thoracic Surgery</i> , 2012, 94, e163-e168.	0.7	4
310	The Treatment of Heart Failure in the 21st Century: Is the Glass Half Empty or Half Full?. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 9, 3.	0.5	4
311	Colchicine and the Failing Heart. <i>JACC: Heart Failure</i> , 2014, 2, 138-140.	1.9	4
312	Association of quality of life with anticoagulant control in patients with heart failure: The Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. <i>International Journal of Cardiology</i> , 2014, 177, 715-717.	0.8	4
313	Can Mr. Trump Make Translational Research Great Again?. <i>JACC Basic To Translational Science</i> , 2017, 2, 101-103.	1.9	4
314	Recognition of self-DNA drives cardiac inflammation: why broken hearts fail. <i>Nature Medicine</i> , 2017, 23, 1400-1401.	15.2	4
315	Incident Heart Failure in Chronic Inflammatory Diseases. <i>JACC: Heart Failure</i> , 2020, 8, 499-500.	1.9	4
316	An early relook identifies high-risk trajectories in ambulatory advanced heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 104-112.	0.3	4
317	Restoring public trust in scientific research by reducing conflicts of interest. <i>Journal of Clinical Investigation</i> , 2019, 129, 3971-3973.	3.9	4
318	Doppler and two-dimensional echocardiographic diagnosis of Björk-Shiley prosthetic valve malfunction: Importance of interventricular septal motion and the timing of onset of valve flow. <i>Journal of the American College of Cardiology</i> , 1986, 8, 971-974.	1.2	3
319	Cardiac Remodeling as Therapeutic Target: Treating Heart Failure with Cardiac Support Devices. <i>Heart Failure Reviews</i> , 2005, 10, 93-94.	1.7	3
320	Molecular Imaging and the Failing Heart. <i>JACC: Cardiovascular Imaging</i> , 2009, 2, 199-201.	2.3	3
321	The Heart Failure Society of America in 2020: A Vision for the Future. <i>Journal of Cardiac Failure</i> , 2012, 18, 90-93.	0.7	3
322	Statement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States: Executive Summary. <i>Circulation: Heart Failure</i> , 2013, 6, 145-150.	1.6	3
323	Light Chains and the Failing Heart. <i>JACC: Heart Failure</i> , 2015, 3, 626-628.	1.9	3
324	Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). <i>American Journal of Cardiology</i> , 2018, 122, 821-827.	0.7	3

#	ARTICLE	IF	CITATIONS
325	Heart Failure 2021. <i>Circulation Research</i> , 2021, 128, 1419-1420.	2.0	3
326	Myocardial dysfunction in septic shock: basic mechanisms and emerging concepts. <i>Current Opinion in Anaesthesiology</i> , 1994, 7, 26-32.	0.9	2
327	Heart failure 2008: an update for clinicians. <i>Current Opinion in Cardiology</i> , 2008, 23, 227.	0.8	2
328	Highlights of the 2009 Scientific Sessions of the Heart Failure Society of America, Boston, MA, September 13-16, 2009. <i>Journal of Cardiac Failure</i> , 2010, 16, 2-8.	0.7	2
329	Guidelines are Merely Guidelines. <i>Journal of Cardiac Failure</i> , 2011, 17, 208-209.	0.7	2
330	Searching for the perfect agent to improve cardiac contractility. <i>Lancet, The</i> , 2016, 388, 2845-2847.	6.3	2
331	Potential Effect of Brexit on Cardiovascular Translational Science. <i>JACC Basic To Translational Science</i> , 2016, 1, 416-417.	1.9	2
332	Will the Precision Medicine Initiative Transform Cardiovascular Translational Research?. <i>JACC Basic To Translational Science</i> , 2016, 1, 298-299.	1.9	2
333	High-Resolution Chromatin Mapping in Heart Failure. <i>Circulation</i> , 2017, 136, 1626-1628.	1.6	2
334	Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients. <i>JACC: Heart Failure</i> , 2017, 5, 603-610.	1.9	2
335	Diagnostic accuracy of damage-associated molecular patterns (DAMPs) in patients with heart failure with a reduced ejection fraction. <i>Journal of Clinical and Translational Science</i> , 2017, 1, 208-209.	0.3	2
336	Current Education of Physicians: Lost in Translation?. <i>JACC Basic To Translational Science</i> , 2019, 4, 655-657.	1.9	2
337	Targeted gene silencing of tumor necrosis factor attenuates the negative inotropic effects of lipopolysaccharide in isolated contracting cardiac myocytes. <i>Texas Heart Institute Journal</i> , 2008, 35, 16-21.	0.1	2
338	Activation of Inflammatory Mediators in Heart Failure. , 2011, , 163-184.		1
339	Update: Shortness of Breath. <i>Circulation</i> , 2014, 129, e447-9.	1.6	1
340	Diabetic Cardiomyopathy: Distinct and Preventable Entity or Inevitable Consequence?. <i>Current Cardiovascular Risk Reports</i> , 2014, 8, 1.	0.8	1
341	JACC: Basic to Translational Science. <i>JACC Basic To Translational Science</i> , 2016, 1, 190-191.	1.9	1
342	The 2017 March for Science. <i>JACC Basic To Translational Science</i> , 2017, 2, 344-345.	1.9	1

#	ARTICLE	IF	CITATIONS
343	Empagliflozin and the Prevention of Heart Failure. JACC Basic To Translational Science, 2017, 2, 355-357.	1.9	1
344	What Are the Off-Target Effects of Planar Lipid Bilayers For Translational Investigators?. JACC Basic To Translational Science, 2019, 4, 132-133.	1.9	1
345	Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction. European Journal of Clinical Investigation, 2019, 49, e13092.	1.7	1
346	Role of Innate Immunity in Heart Failure. , 2020, , 103-114.e2.		1
347	Abstract 1949: The Protein Kinase MAP4K4 Is Activated in Failing Human Hearts and Mediates Cardiomyocyte Apoptosis in Experimental Models, in vitro and in vivo. Circulation, 2007, 116, .	1.6	1
348	Cardiac Adrenergic Activation in Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2022, 7, 128-130.	1.9	1
349	Making Science Fun Again. JACC Basic To Translational Science, 2022, 7, 311-312.	1.9	1
350	Endothelin Antagonism and the Failing Heart: an Unfilled Promise, an Unmet Need, or an Unanswered Question?. Journal of Molecular and Cellular Cardiology, 2002, 34, 1131-1133.	0.9	0
351	Can valsartan reduce the occurrence of atrial fibrillation in heart failure patients?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 502-503.	3.3	0
352	Angiotensin Receptor Blockers in the Treatment of Heart Failure. , 0, , 44-56.		0
353	Mechanisms of idiopathic dilated cardiomyopathies. Current Opinion in Organ Transplantation, 2006, 11, 553-559.	0.8	0
354	Improved propensity matching for heart failure using neural gas and self-organizing maps. , 2009, , .		0
355	Unsupervised cluster analysis and mortality risk in the Digitalis Investigation Group (DIG) trial of heart failure. , 2009, , .		0
356	Letter by Taylor et al Regarding Article, "Hydralazine and Isosorbide Dinitrate in Heart Failure: Historical Perspectives, Mechanisms, and Future Directions" Circulation, 2011, 124, e778; author reply e779.	1.6	0
357	The Role of Cytokines in Clinical Heart Failure. , 2015, , 191-203.		0
358	Training the Next Generation of Translational Cardiovascular Investigators. JACC Basic To Translational Science, 2016, 1, 554-556.	1.9	0
359	JACC: Basic to Translational Science. Journal of the American College of Cardiology, 2017, 69, 1093-1094.	1.2	0
360	Deus Ex Machina. JACC Basic To Translational Science, 2017, 2, 227-228.	1.9	0

#	ARTICLE	IF	CITATIONS
361	Inflammatory Mediators in Heart Failure. , 2018, , 33-50.		0
362	Can One Person Make a Difference?. JACC Basic To Translational Science, 2019, 4, 868-869.	1.9	0
363	Alterations in Ventricular Structure. , 2020, , 166-180.e3.		0
364	Why Do Medical Journals Exist in the 21st Century?. JACC Basic To Translational Science, 2020, 5, 969-970.	1.9	0
365	JACC: Basic to Translational Science and Preprint Servers. JACC Basic To Translational Science, 2020, 5, 107-108.	1.9	0
366	Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure. Journal of Physiology and Biochemistry, 2021, 77, 295-304.	1.3	0
367	The clinical experience with anti-cytokine therapy in heart failure. , 2003, , 95-110.		0
368	Abstract 205: Dysfunction of the 19S Proteasome Contributes to Adverse Cardiac Remodeling in Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor. Circulation, 2007, 116, .	1.6	0
369	Abstract 2915: Circulating Fas in Subjects with Acute Cardiomyopathy and Myocarditis: Results from IMAC 1. Circulation, 2007, 116, .	1.6	0
370	Abstract 1770: Proteasome Switching is Associated with Adverse Cardiac Remodeling in a Transgenic Mouse Model of Sustained Inflammatory Signaling. Circulation, 2008, 118, .	1.6	0
371	The role of cytokines in inflammation-induced cardiomyopathy: Pathogenesis and therapeutic implications. , 2010, , 171-181.		0
372	Molecular and Cellular Mechanisms for Myocardial Recovery. , 2011, , 119-133.		0
373	Device Autonomic Regulation Therapy in Patients with Heart Failure and Reduced Ejection Fraction. Journal of Atrial Fibrillation, 2020, 13, 2409.	0.5	0
374	Recent Insights into the Molecular Pathophysiology of Viral Myocarditis. , 2005, , 145-153.		0
375	The Role of Cardiac Restraint Devices in the Treatment of Patients with Dilated Cardiomyopathy. , 0, , 59-67.		0
376	Could Nephilysin Be Already Inhibited by BNP in the LIFE Trial? Reply. JAMA Cardiology, 2022, , .	3.0	0